A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination with Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

Primary Objective

To determine the RP2D for FT516 as monotherapy (r/r AML), and in combination with rituximab or obinutuzumab (r/r B-cell lymphoma) To evaluate the safety and tolerability of FT516 as monotherapy following CY/FLU conditioning (r/r AML), and in combination with rituximab or obinutuzumab following CY/FLU conditioning (r/r B-cell lymphoma) To evaluate the safety and tolerability of FT516 in combination with rituximab or obinutuzumab following bendamustine conditioning (r/r B-cell lymphoma)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Locations

University of Colorado Hospital

Principal Investigator
Photograph of Manali Kamdar,  MD

Manali Kamdar, MD

Study ID

Protocol Number: 21-3986

More information available at ClinicalTrials.gov: NCT04023071

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers